Heart Podcast Cardiac imaging in oncology: the detection of cardiotoxicity
Feb 10, 2026
Professor Kazuaki Negishi, cardiologist and UNSW professor specialising in cardio-oncology and cardiac imaging. He discusses using imaging to spot cancer therapy heart effects early. Topics include categories of treatment-related cardiac toxicity, when to use echo, GLS, MRI and CT, GLS‑guided cardioprotection trials, practical surveillance workflows and detection of immune checkpoint myocarditis.
AI Snips
Chapters
Transcript
Episode notes
Cancer Care Has Become Chronic
- Cancer survival has shifted care from terminal treatment to chronic survivorship.
- This change makes cardiovascular complications from cancer therapy a leading non-cancer cause of morbidity and mortality.
CTR-CVT Is Multi-Modal
- Cancer therapy–related cardiovascular toxicity (CTR-CVT) spans five categories: cardiac dysfunction, myocarditis, vascular toxicity, hypertension, and arrhythmia.
- Different drug classes map to different cardiac risks, so CTR-CVT is not a single disease.
Make Echo With GLS Your First Test
- Use transthoracic echocardiography (TTE) as the first-line monitoring tool, preferring 3D EF when available.
- Add global longitudinal strain (GLS) to detect subclinical dysfunction before EF declines.